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Abstract
Background: Due to improvements in cancer survival the number of people of working age living with cancer
across Europe is likely to increase. UK governments have made commitments to reduce the number of working
days lost to ill-health and to improve access to vocational rehabilitation (VR) services. Return to work for people
with cancer has been identified as a priority. However, there are few services to support people to remain in or
return to work after cancer and no associated trials to assess their impact. A pilot randomised controlled trial
among women with breast cancer has been designed to assess the feasibility of a larger definitive trial of VR
services for people with cancer.
Methods: Patients are being recruited from three clinical sites in two Scottish National Health Service (NHS) Boards
for 6 months. Eligible patients are all women who are: (1) aged between 18 and 65 years; (2) in paid employment
or self-employed; (3) living or working in Lothian or Tayside, Scotland, UK; (4) diagnosed with an invasive breast
cancer tumour; (5) treated first with surgery. Patients are randomly allocated to receive referral to a VR service or
usual care, which involves no formal employment support. The primary outcome measure is self-reported sickness
absence in the first 6 months following surgery. Secondary outcome measures include changes in quality of life
(FACT-B), fatigue (FACIT-Fatigue) and employment status between baseline and 6- and 12-months post-surgery.
A post-trial evaluation will be conducted to assess the acceptability of the intervention among participants and the
feasibility of a larger, more definitive, trial with patients with lung and prostate cancer.
Discussion: To our knowledge this is the first study to determine the feasibility of a randomised controlled trial of
the effectiveness of VR services to enable people with cancer to remain in or return to employment. The study will
provide evidence to assess the relevance and feasibility of a larger future trial involving patients with breast,
prostate or lung cancer and inform the development of appropriate VR services for people living with cancer.
Trial Registration: ISRCTN: ISRCTN29666484
Registration date: 07/10/10; Randomisation of first patient: 03/12/10
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Background
Due to improvements in cancer survival the number of
people of working age living with cancer across Europe is
likely to increase [1]. It is estimated that more than
500,000 people in the UK under the age of 65 years have
been diagnosed with cancer during their working lives [2].
Every year in Scotland around 27,400 people are diagnosed
with cancer, 52% (n = 14,300) of whom are women [3].
Breast cancer is the most commonly diagnosed cancer in
Scottish women and incidence has increased by 8% over
the past decade attributed, in part, to earlier detection due
to mammography screening programmes [3]. In 2007 over
half (55%) of all women diagnosed with breast cancer in
Scotland were of working age (i.e., between 18 and
65 years): around 1 in 20 were under 40 years, and 1 in 5
were under 50 years [4]. Despite notable variation across
countries, [5] breast cancer mortality rates are decreasing
across Europe[6,7]. In a recent comparative analysis of 30
European countries, England and Wales, Scotland, and
Northern Ireland had the second, fourth and fifth largest
overall decline in mortality between 1989 and 2006 of 35%,
30% and 29%, respectively [5]. There is evidence that the
trends of increasing incidence [8] and decreasing mortality
will continue [5]. Remaining in or returning to work will
therefore be increasingly important for women living with
breast cancer in Scotland and across the UK and Europe.
Dame Carol Black’s recent review of the health of
Britain’s working age population recommended a multi-
agency and partnership approach to supporting people
to remain in or return to work and highlighted the role
of line managers, general practitioners (GP) and voca-
tional rehabilitation (VR) services[9]. UK governments
have made commitments to reduce the number of
working days lost to ill-health and to improve access to
VR services. In Scotland, the Scottish Centre for Healthy
Working Lives (SCHWL) has established pilot VR ser-
vices in National Health Service (NHS) Tayside and
NHS Lothian. These services support people to remain
in or return to work by providing fast-track care and
services such as physiotherapy, counselling and occupa-
tional therapy to employees from small- to medium-
sized companies with less than 250 employees, where
occupational health support services are not available.
The Scottish Government has recently identified return
to work for people living with cancer as a priority [10].
People with cancer can often experience changed work-
place relations or employment status following diagnosis
or during treatment, with negative financial and psychoso-
cial consequences. It is known that individuals change
jobs, leave paid employment or experience a decline in
earnings [11]. Individuals may also experience discrimina-
tion from employers or colleagues [11]. However, a recent
review has identified that there are few services to support
people to remain in or return to work after cancer and no
associated trials to assess their impact [11].
The SCHWL and Macmillan Cancer Support are
developing plans to expand VR services to people with
cancer. The establishment of pilot VR services across
Scotland may provide an opportunity to conduct a large
randomised controlled trial to evaluate their effective-
ness for people living with cancer. However, there are
several uncertainties that must be addressed including
an assessment of the feasibility of such a trial and the
acceptability of the intervention among people with can-
cer. Given increasing incidence and survival of people
living with breast cancer, it is both timely and appropri-
ate to determine the feasibility of this definitive trial
through a pilot randomised controlled trial (RCT) of VR
services among women following surgery for breast can-
cer. A study design incorporating a pilot RCT was
selected to refine, and assess the feasibility of, trial pro-
cesses (including, recruitment, randomisation and fol-
low-up) and estimate the likely effect size in advance of
a larger, more definitive, future trial.
Aim
The aim of this study is to determine the feasibility of
an RCT of VR services among women with breast can-
cer following surgery and whether this intervention is
acceptable in this patient group.
Objectives
1. Determine the numbers of patients in Lothian and
Tayside with breast cancer referred for surgery who are
in paid or self-employment and potentially eligible for
the RCT.
2. Assess whether it is feasible and acceptable to
recruit patients into the trial post-operatively. If not,
identify the most appropriate timing for recruitment
and the employment intervention that follows.
3. Estimate trial recruitment rates (i.e., percentage of
eligible women who consent to the trial) and attrition
over the period of the trial.
4. Determine whether the outcomes are measurable
and appropriate, and evaluate the instruments used to
measure secondary outcomes (i.e., FACT-B, FACIT-
Fatigue).
5. Estimate the likely effect size to inform the power
calculation for a larger, more definitive trial.
6. Assess the feasibility of including patients with lung
and prostate cancer in a larger future RCT.
Methods
Design
The design of this feasibility study is an interventional
two-arm RCT (Figure 1).
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Figure 1 Study Design Flowchart: enrolment, randomisation and follow-up.
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Setting and participants
Patients with breast cancer are being recruited from
three hospitals in two NHS Boards in Scotland (Perth
Royal Infirmary (PRI), and Ninewells Hospital, Dundee
[NHS Tayside]; Western General Hospital (WGH),
Edinburgh [NHS Lothian]). Recruitment to the trial is
proceeding for 6 months at each site.
Eligibility
Eligible patients are all women who are: (1) aged
between 18 and 65 years; (2) in paid employment or
self-employed; (3) living or working in Lothian or Tay-
side, Scotland, UK; (4) diagnosed with an invasive breast
cancer tumour; (5) treated first with surgery. Patients
diagnosed with Ductal Carcinoma in Situ (DCIS) are
excluded. Patients are not excluded on the basis of com-
munication difficulties. Interpretation and translation
services will be used for participants unable to commu-
nicate in English. Patients with learning difficulties are
also not excluded as a study investigator (GH) has
expertise involving people with learning difficulties in
research.
Sample size calculation
There are several uncertainties that this feasibility study
seeks to address before a larger, more definitive RCT of
vocational rehabilitation services for people with cancer
can be conducted. These uncertainties include: (1) the
number of women who may be eligible for inclusion in
the trial; (2) the percentage of eligible women who meet
the VR services’ criteria for referral; (3) the recruitment
rate, defined as the percentage of eligible women who
consent to involvement in the trial. The feasibility study
will therefore provide evidence to inform sample size
calculations for a larger trial. However, we estimate that
between 66 and 79 patients will be recruited to the fea-
sibility study over a 6 month period. This sample size is
based on diagnosis and surgical data obtained from
2008, estimated employment rates, and a conservative
recruitment rate of between 50% and 60%.
The feasibility study is also assessing the likely effect
size to inform sample size calculations for a potential
larger future trial. The primary outcome measure is the
number of days off work in the 6 months following sur-
gery. One report indicated that the mean length of time
absent from work after a diagnosis of breast cancer was
5.6 months [12]. Assuming, therefore, a mean of
180 days absent from work in the control group and an
estimated standard deviation of 100 days, with a sample
size of 70 (35 in each group), the study would be able to
detect a reduction in number of days absent from work
from 180 to 110 days with 5% level of significance and
80% power. A larger sample size would be required to
detect smaller differences. To detect a reduction in
number of days absence by 2 months, a sample size of
88 patients (44 in each group) would be required.
To detect a reduction of 1 month, a sample size of 350
(175 in each group) would be required.
Patient Recruitment
Recruitment and obtaining written informed consent to
be involved in the study is occurring before participants
are randomly assigned to the intervention or usual care
arm of the study. Breast care nurses are initially applying
the inclusion criteria to patients attending hospital in the
pre-operative phase. Due to variation in local clinical pro-
cesses, service size and workforce capacity the recruit-
ment process differs in each of the three hospitals.
Perth Royal Infirmary (PRI)
Women who are eligible for inclusion in the RCT are
identified from surgical lists by clinical teams. Eligible
women are given information about the study by their
breast care nurse at a pre-operative appointment. Writ-
ten informed consent is taken at a face-to-face meeting
with a researcher (RGK) when women attend hospital
for a post-operative clinic appointment.
Ninewells Hospital, Dundee
Eligible women are identified from surgical lists by
clinical teams and are given a pack of information
about the study when they attend hospital for surgery.
Women return this information pack to their breast
care nurse when they leave hospital the following day
or by post to a researcher (RGK). Those who agree to
participate include their written informed consent in
their returned pack.
Western General Hospital (WGH), Edinburgh
Eligible women are identified by clinical teams from sta-
ging information discussed at a weekly multi-disciplinary
team meeting. Eligible women are given a pack of study
information by their breast care nurse when they attend
hospital for a pre-operative appointment and return this
to their breast care nurse when they attend for surgery
or by post to a researcher (RGK). Those who agree to
take part in the trial include their written informed con-
sent in the returned information pack.
In each hospital, patients who do not want to partici-
pate are asked if they consent to the retention of a lim-
ited set of anonymised clinical, sociodemographic and
employment data (e.g., age, sex, postcode, diagnosis,
treatment, employment status) so that a comparison can
be made between patients who do and do not agree to
be approached (Figure 1). Data are recorded on the
number of patients who are eligible and reasons for
ineligibility, the numbers who consent to participate in
the trial and the numbers who consent to retention of
anonymised data.
Randomisation
The allocation sequence was generated from a Bernoulli
probability distribution with a specified probability of
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0.5 which ensures participants have an equal chance of
being in either group. Participants are randomly
assigned to the intervention and usual care arm with a
1:1 allocation ratio (Figure 1). A separate sequence is
used for each NHS Board (analogous to the VR service
to which participants in the intervention arm are
referred) to ensure that there is an even distribution of
participants to the intervention and usual care groups in
each NHS Board. The allocation sequences are con-
cealed from the researchers responsible for recruiting
patients into the trial (RGK), data collection (RGK) and
data analysis (RGK, JE, NMG, GH). The trial statistician
(DA) provided the allocation sequences to an adminis-
trator in the Cancer Care Research Centre at the Uni-
versity of Stirling who is not involved in the process of
random number generation nor data collection and ana-
lysis. This individual will assign patients to the interven-
tion and usual care groups and refer patients in the
intervention arm to the VR service.
Blinding
It will be clear to most patients whether or not they
have been assigned to the intervention or usual care
arm of the study. Thus, it is not possible to blind
patients to their group allocation. However, the rando-
misation procedure outlined above ensures that those
involved in data collection and analysis will not know to
which group patients have been randomly assigned.
Intervention
The complex intervention is referral to a VR service in
either Tayside or Lothian (Figure 1). Patients recruited
from PRI and Ninewells, Dundee are randomised to
receive referral to a VR service in Tayside; individuals
enrolled from WGH are referred to a VR service in
Lothian. All participants allocated to the intervention
arm of the trial are contacted by a VR service by tele-
phone within 10 days following return of the baseline
questionnaire to the researcher (RGK). Participants are
allocated a ‘case manager’ who conducts a telephone
assessment of supportive care needs to facilitate remain-
ing in or returning to work during which baseline
measures are also recorded using the Canadian Occupa-
tional Performance Measure (COPM) [13], 12 item Gen-
eral Health Questionnaire (GHQ-12) [14] and European
Quality of Life - 5 Dimensions (EQ-5D) [15]. Outcomes
are re-measured at 3- and 6-months from referral.
Based on this initial assessment of each individual’s per-
sonal goals and health status the case manager signposts
participants to appropriate support services including
physiotherapy, occupational therapy, occupational health
nurse, occupational health doctor, counsellor/psycholo-
gical therapy, complementary therapy. Each individual
may therefore receive a different (combination of) inter-
vention(s). Usual care following surgery involves no
formal employment support. Participants in both arms
of the trial receive a copy of the booklet Work and Can-
cer published by Macmillan Cancer Support [16].
As the personalised and complex nature of the inter-
vention precludes exogenous standardisation, data will
be obtained from each service on the specific interven-
tions received by individuals in the intervention arm of
the pilot RCT. Secondary analysis of outcome measures
recorded by each service at initial assessment and
3- and 6-month follow up will also be undertaken for
these women. In addition, information will be gathered
about each service (e.g., size, workforce composition,
ethos) to contextualise possible differences in reported
outcomes between VR services.
Data collection
Data to evaluate the intervention in terms of quality of
life, fatigue and change in employment status are col-
lected at baseline, 6 months and 12 months after entry
to the trial via a self-completion questionnaire. In
addition, self-reported sickness absence is collected
every four weeks for the first 6 months of follow-up
and for the four weeks before the 12-month follow-up
time point (Figure 1). A telephone reminder is admi-
nistered if questionnaires are not returned within
10 days. Participants have the option of a researcher
collecting their responses to all questionnaires by
telephone.
Outcome measures
Primary outcome
The primary outcome measure is self-reported number
of days off work due to ill-health within the first six
months after surgery.
There are two main ways of measuring absence from
work: (1) sick leave register at participants’ place of
employment; (2) participant self-report. Although a sick
leave register managed by the employer is regarded as
the gold standard, self-report is also robust [17]. One
study found more than 96% accuracy between register
and self-report when the recall period is limited to 2 to
4 weeks [18]. The feasibility of using sick leave registers
will be determined by asking participants to consent to
contact with their employers to access their sick leave
register at the end of the 6 month follow-up period.
Secondary outcomes
Secondary outcome measures are changes in quality of
life (QoL), fatigue and employment status.
Quality of life The Functional Assessment of Cancer
Therapy-Breast Cancer (FACT-B) Version 4 will be used
to assess breast cancer related QoL [19]. The FACT-B is
a 37-item self-report questionnaire that evaluates several
QoL domains: physical, social/family, emotional, and
functional well being. In addition, a 10-item breast
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cancer subscale (BCS) is specific to the experiences of
women living with breast cancer and the symptoms and
side-effects of treatment and includes items on anxiety,
pain and body image. Participants complete the ques-
tionnaire in terms of the past 7 days and each item is
scored on a 5-point scale that varies from 0 (not at all)
to 4 (very much). Negatively phrased questions are
reversed prior to analysis and scores are summed for
each domain and a higher score indicates higher well
being [20]. Domain scores vary from 0 to 28 for the
physical, social/family and functional well being
domains; 0 to 24 for the emotional well being domain;
and 0 to 40 for the BCS. The scores of the four well-
being domains are summed to calculate the Functional
Assessment of Cancer Therapy-General (FACT-G) score
and total scores of the FACT-G and BCS are summed
to calculate a FACT-B score.
Fatigue The Functional Assessment of Chronic Illness
Therapy-Fatigue Scale (FACIT-Fatigue) is used to assess
specific functional and physical aspects of fatigue asso-
ciated with breast cancer diagnosis and treatment. This
13-item subscale has been determined to be a reliable
and valid stand alone measure of fatigue [21]. In com-
mon with the FACT-B, items are scored on a 5-point
likert scale and relate to the past 7 days. FACIT-Fatigue
scores vary from 0 to 52 and negatively worded items
are reversed before analysis so that higher scores repre-
sent better self-reported health [20].
Employment status A non-validated questionnaire will
measure change in employment status in terms of five
indicators: earnings, job, role, hours worked, or employ-
ment type (i.e., part-/full-time employment).
Socio-demographic and clinical information A struc-
tured questionnaire is used to collect data on date of
birth, postcode, total household income, clinical diagno-
sis, and other conditions for which participants are cur-
rently receiving treatment. Consent will also be sought
to access participants’ hospital clinical notes to accu-
rately identify diagnosis and treatments administered.
Data analysis
The study will provide data on eligibility, recruitment
rates and possible loss to follow-up informing the feasi-
bility and development of a larger, more definitive,
future trial. The study will also assess the possibility of
stratifying the sample in a larger trial by potential study
confounders such as age, sex, employment type, hours
of work, socio-economic status, co-morbidity and cancer
stage that have previously been identified as impacting
on length of absence from work [11].
As this is a feasibility study, hypothesis testing must
proceed cautiously. However, it is anticipated that parti-
cipants referred to VR services will experience fewer
days off work due to sickness, lower levels of fatigue
and increased QoL. QoL measures will be analysed at
global (i.e., summed FACT-G and FACT-B scores), sub-
scale (i.e., physical, social/family, emotional, functional,
BCS), and individual question level. This will also enable
evaluation of the outcome questionnaire’s ability to
detect differences in QoL between the intervention and
control group associated with VR intervention. The
greatest difference may be detectable at the level of indi-
vidual domains of well-being (particularly, emotional,
social/family and functional) and individual questions
included in these domains (e.g., “I am satisfied with how
I am coping with my illness” [GE2], “I feel close to my
friends” [GS1], “I get support from my friends” [GS3],
“I am able to work (include work at home)” [GF1], “My
work (include work at home) is fulfilling” [GF2]) as sup-
port to remain in or return to employment may increase
emotional well-being, enable access to a wider network
of social support through colleagues, and increase physi-
cal functioning.
Statistics
Data analysis will be conducted using PASW Statistics
(Version 17) [22]. Baseline characteristics will be
reported as mean and standard deviation for continuous
data and n (%) for categorical data. Differences between
the intervention and control groups for the primary out-
come measure will be tested using an independent sam-
ples t-test. Differences between groups in secondary
outcome measures will be examined by analysis of cov-
ariance adjusting for baseline values. Significance level is
set at 0.05.
Post-trial evaluation
Acceptability of the trial and VR intervention among trial
participants
A patient-centred evaluation of the acceptability of the
trial will be conducted by interviewing participants in
each arm of the trial. Semi-structured telephone inter-
views will elicit participants’ views on the acceptability
of participating in the trial, the method and timing of
recruitment and their opinions about approaching their
employers directly. Maximum variation sampling will be
used to initially identify 5 patients in each arm of the
trial. Key variables in the sampling frame will include:
current employment status (i.e., at/off work), job, role,
tenure (i.e., part-/full-time), age, diagnosis, treatment
pathway. Interviewing and analysis will proceed concur-
rently to pinpoint data saturation, and further rounds of
interviews will be conducted with new participants, if
required. The interviews will be digitally recorded and
transcribed. NVivo (Version 8) [23] will support data
management and qualitative analysis. Transcripts will be
analysed thematically using the Framework approach
[24], which is a method that provides a structure within
which qualitative data are organised and in which
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themes are identified between participants and groups of
participants. Data are processed through stages that
familiarise the researcher with the content and enable
indexing and coding. Thematic matrices are developed
that preserve the richness of the data and enable data to
be categorised and compared thematically. Data collec-
tion will be conducted by two study researchers (RGK,
BC). Analysis will be conducted by RGK, BC, NMG, JE
and GH.
Feasibility of including patients with lung and prostate
cancer in a future RCT
Health Professional Interviews Semi-structured face-
to-face interviews will be conducted with purposively
sampled staff from the lung and prostate cancer clinical
teams (1 consultant and 1 Clinical Nurse Specialist
(CNS) from each team [n = 4]), staff from the VR ser-
vices in Tayside and Lothian (1 service manager and 1
case manager from each service [n = 4]). Interviews will
elicit views on the acceptability of the pilot RCT (e.g.,
the method and timing of recruitment, eligibility cri-
teria) and the feasibility of including patients with lung
or prostate cancer in a future RCT.
Patient Interviews Face-to-face semi-structured inter-
views will also be conducted with people with either
lung or prostate cancer. Individuals will be identified
from clinical databases and recruited from the hospital
at an appointment with their consultant. Interviews will
elicit views on the acceptability of VR intervention and
prospective trial participation, and explore employment
issues that may have been encountered following diag-
nosis and treatment. Maximum variation sampling will
be used to initially identify 5 patients with lung cancer
and 5 people with prostate cancer. Key variables in the
sampling frame will include: current employment status
(i.e., at/off work), job, role, tenure (i.e., part-/full-time),
age, diagnosis, treatment pathway. Individuals who were
first treated with surgery will be approached to enable
comparison with the group of women in the pilot RCT.
Interviewing and analysis will proceed concurrently to
pinpoint data saturation, and further rounds of inter-
views will be conducted with new participants, if
required. The interviews will be recorded and tran-
scribed and the transcripts analysed thematically using
the Framework approach [24] supported by NVivo qua-
litative analysis software [23]. Data collection will be
conducted by RGK and BC. Analysis will be conducted
by RGK, BC, NMG, JE and GH.
Ethical considerations
The study protocol has been approved by NHS Tayside
Committee on Medical Research Ethics A (Ref: 10/S1401/
15) and the ethics committee of the University of Stirling.
Research Governance approval was also obtained from
NHS Lothian and NHS Tayside. Informed written consent
is obtained from each participant. The participant infor-
mation sheet provides contact details and a telephone
number of the study’s principal investigator (GH) and an
independent contact to whom queries may be directed
during the study period. With the participant’s consent
their GP and consultant is informed of their involvement
in the study in accordance with good practice ethical
guidelines.
Data storage and confidentiality
All questionnaires, interview transcripts and consent
forms will be stored securely in a locked filing cabinet.
Quantitative and qualitative data are entered into pass-
word protected databases (PASW Statistics [Version 17]
[22] and NVivo [Version 8] [23], respectively) in anon-
ymised form and access is restricted to members of the
research team. Following completion of the study, data
will be archived and stored securely for 10 years in
accordance with University of Stirling policy.
Risks
The main known risk to participants is that those who
are in the usual care arm of the study may feel
aggrieved that they have not received support from a
VR service. However, the participant information sheet
explains clearly that there is a chance that individuals
may not be randomly allocated to the intervention
group. There is also the potential that all participants
involved in the study may feel pressured to return to
work because its focus is employment. However, the
Macmillan Cancer Support booklet Work and Cancer
that all participants receive makes it clear that patients
should only remain in or return to work when they feel
physically and mentally able to do so[16]. Study investi-
gators will also reinforce this message in each encounter
with participants.
Discussion
To our knowledge this is the first study to determine
the feasibility of an RCT to assess the effectiveness of
VR services to enable people with cancer to remain in
or return to employment. The study will provide evi-
dence to assess the relevance and feasibility of a larger
future trial involving patients with breast, prostate or
lung cancer. VR services may assist patients with cancer
maintain their income, identity, and social networks,
and improve quality of life potentially mitigating the
negative financial and psychosocial consequences often
associated with changes in employment status following
cancer diagnosis or during treatment. Findings from this
research will therefore inform the future development of
appropriate VR services for people living with cancer,
particularly for women with breast cancer following
surgery.
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